Noxilizer Management Team
Lawrence Bruder, President & CEO, brings over 25 years of leadership and operational experience in large and small life science companies, including Becton Dickinson, Applied Biosystems, Leica, Olympus, and Guava Technologies. Most recently he was President and CEO of venture-backed Guava Technologies, which was sold to Millipore Biosciences in 2009. Most of his experience prior to Guava was at Becton Dickinson, where he held a number of significant positions over a 10-year period. His responsibilities in both companies included the clinical and regulatory aspects of 510(k) submittals to the FDA for medical devices, significant commercial interaction with pharmaceutical companies, and high-level business development transactional activity; all of these being a critical part of Noxilizer’s needs. Mr. Bruder holds a B.S. from Rochester Institute of Technology and Master of Management in Marketing & Economics from the Kellogg Graduate School at Northwestern University.
David Chaskin, Chief Financial Officer (CFO), has over 25 years of accounting and financial reporting experience in a variety of strategic and financial executive roles. Most recently, he served as CFO for Aritas Group, Inc., a financial holding company, and the Financial and Operations Principal for the US broker dealer subsidiary, Aritas Securities LLC. Mr. Chaskin joined Aritas Group, Inc. a few months after its product launch and helped it grow into a company that achieved tens of millions of dollars of revenue.In the second quarter of 2012, Mr. Chaskin assisted in the sale of the operating businesses of Aritas Group Inc. Prior to Aritas, Mr. Chaskin held a variety of financial roles for large, publicly-traded companies including Chemical Bank, Guess? and TBA Entertainment, and lead financial positions with smaller, privately-held companies including Exenet Technologies and ArisGlobal. Mr. Chaskin received his B.S from Lehigh University and his MBA from Fordham University.
Maura O. Kahn, Vice President, Business Development and Marketing, has 20 years of health care experience. Most recently, Maura was Senior Director of Marketing at MedImmune, responsible for developing and executing the marketing strategy and plan for Synagis. This franchise represents over 80% of total revenue for the company. Maura spent nine years at Eli Lilly in US Diabetes Marketing, Sales Management, Business Development and Global New Product Planning. She was a member of the US Humalog launch team, led the US launch of the Humulin/Humalog Pen and initiated the first ever direct-to-consumer campaign at Lilly. She was a member of the deal teams in Lilly’s successful negotiations with Takeda for Actos and Amylin for Byetta. She began her career at Targeted Communications and The RTC Group. Her clients included political candidates, trade associations and Fortune 500 companies. Ms. Kahn received her B.A. from Saint Mary’s College in Indiana and her MBA from the Kelley School of Business at Indiana University.
David Opie, Ph.D., Senior Vice President, Research and Development, has extensive medical device development experience with both start-ups and industry leaders, including Johnson & Johnson and Cook Medical. He has employed a thorough knowledge of Good Laboratory Practices, Good Manufacturing Practices, and design control and product development procedures. He has experience with cardiovascular and urological implants, as well as drug delivery market segments. Dr. Opie holds a Ph.D. and an M.S. in Physics from the College of William and Mary, and a B.A. in Physics from the University of Delaware.